CMMB (Chemomab Therapeutics) Debt-to-Equity : 0.02 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Debt-to-Equity?

Chemomab Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.12 Mil. Chemomab Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.21 Mil. Chemomab Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $13.54 Mil. Chemomab Therapeutics's debt to equity for the quarter that ended in Dec. 2024 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Chemomab Therapeutics's Debt-to-Equity or its related term are showing as below:

CMMB' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.04
Current: 0.02

During the past 5 years, the highest Debt-to-Equity Ratio of Chemomab Therapeutics was 0.04. The lowest was 0.01. And the median was 0.02.

CMMB's Debt-to-Equity is ranked better than
89.95% of 1015 companies
in the Biotechnology industry
Industry Median: 0.14 vs CMMB: 0.02

Chemomab Therapeutics Debt-to-Equity Historical Data

The historical data trend for Chemomab Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemomab Therapeutics Debt-to-Equity Chart

Chemomab Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

0.04

0.01

0.02

Chemomab Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.03	0.04	0.02	0.02

Competitive Comparison of Chemomab Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Chemomab Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chemomab Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Chemomab Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Chemomab Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.115	+	0.209)	/	13.537
	=	0.02

Chemomab Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.115	+	0.209)	/	13.537
	=	0.02

Chemomab Therapeutics (NAS:CMMB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Chemomab Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Chemomab Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Chemomab Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (NAS:CMMB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

2QV0:Germany

Address

Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002

Website

https://www.chemomab.com

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Executives

Orbimed Israel Biofund Gp Limited Partnership	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
George Adi Mor	director, 10 percent owner, officer: Chief Executive Officer	15 KAFRISIN ST., TEL AVIV L3 6901658
Neil Harris Cohen	director	C/O ANCHIANO THERAPEUTICS LTD., ONE KENDALL SQ., BLDG 1400E, STE 14-105, CAMBRIDGE MA 02139
Matthew Bejosa Frankel	officer: Chief Medical Officer	672 PROSPECT AVE., PRINCETON NJ 08540
Jill M. Quigley	director	TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Joel Michael Maryles	director	5 ATZMON ST., HASHMONAIM L3 7312700
Donald Marvin	officer: Executive VP, CFO & COO	2094 LOST CANYON RANCH CT, CASTLE ROCK CO 80104
Dale R Pfost	director, officer: Chief Executive Officer	ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Nissim Darvish	director	C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Peter Thiel	10 percent owner	9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Sigal Fatal	officer: Chief Financial Officer	16 KANFEY NESHARIM ST., RAMAT GAN L3 5235716
Arnon Aharon	officer: Chief Medical Officer	12 YAVNE ST., TEL AVIV L3 6579116
Alan Charles Moses	director	C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Stephen P Squinto	director	C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Orbimed Israel Gp Ltd.	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629